– USA, CO – TriSalus Life Sciences Inc. (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today announced the appointment of Liselotte Hyveled to its Board of Directors, bringing over two decades of experience stimulating scientific innovation and advancing pharmaceutical pipelines through research and development excellence.
“We are thrilled to welcome Liselotte to the TriSalus Board of Directors as we commercialize the TriNav Infusion System and progress our pipeline through key milestones in 2024 and beyond. Her wealth of experience and strategic insights will be instrumental in shaping TriSalus’ long-term vision of pioneering innovative treatments for liver and pancreatic cancers. We eagerly anticipate Liselotte’s contributions to our continued success,” said Board Chairman, Mats Wahlstrom.
About Liselotte Hyveled
Liselotte Hyveled is a seasoned executive with over two decades of successfully implementing innovative solutions for challenging chronic diseases within a rapidly changing, highly competitive R&D environment. Currently serving as the Chief Patient Officer at Novo Nordisk, she is responsible for ensuring the integration of patient needs and perspectives into the company’s decision-making processes and operations, from inception to commercialization. Ms. Hyveled’s tenure at Novo Nordisk has been marked by numerous leadership positions and contributions, reflecting her commitment to R&D excellence, breakthrough innovation, and advancing patient-centric solutions. She has initiated several social responsibility initiatives at Novo Nordisk with a focus on neurodiversity, disabilities and generational intelligence.
Liselotte Hyveled said, “TriSalus has developed a truly groundbreaking platform aimed at addressing the complexities of liver and pancreatic cancers, positioning itself for a pivotal phase of expansion. I am honored to collaborate with the TriSalus board and leadership team to build upon the company’s achievements and realize its vision of transforming patient outcomes.”
Ms. Hyveled holds a Master of Pharmacy Science from Copenhagen University and a Master of Medical Business Strategies from Copenhagen Business School.
About TriSalus Life Sciences
TriSalus Life Sciences is an oncology-focused medical technology business providing disruptive drug delivery technology to improve therapeutics delivery to liver and pancreatic tumors.
SOURCE: https://trisaluslifesci.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.